Abstract
Astrocyte dysfunction is increasingly recognized as a contributor to neurodevelopmental disorders, yet precise mechanisms remain elusive. Here, we identify IGFBP2 as a key astrocyte-derived inhibitor of synaptogenesis in Rett syndrome. We show that an IGF1-derived peptide, IGF1(1-3), depletes IGFBP2 via proteasomal degradation. This restores IGF1 bioavailability and rescues synaptic function in a non-cell-autonomous manner. These findings provide a mechanistic explanation for the clinical efficacy of IGF1 peptide and its mimetics in Rett syndrome, and highlight astrocytes as rational therapeutic targets in neurodevelopmental and other disorders.
Introduction
Rett Syndrome (RTT) is a severe neurodevelopmental disorder primarily caused by mutations in the X-linked gene MECP2. While historically considered a neuron-intrinsic pathology, recent research has highlighted the critical role of astrocytes in RTT progression. Mutant astrocytes have been shown to actively impair neuronal maturation and synapse formation through non-cell-autonomous mechanisms. Clinical trials using IGF1-derived peptides, such as the FDA-approved Trofinetide, have demonstrated therapeutic benefits, yet the underlying molecular mechanism has remained poorly understood. This study investigates how these peptides interact with astrocyte-secreted factors to restore neuronal health.
Experimental Design and Methods
To decouple the contributions of astrocytes and neurons, researchers employed an indirect co-culture system using wild-type (WT) and MECP2 knockout (KO) mouse cells. Neurons and astrocytes were grown in shared media but separated by a permeable membrane, allowing for the study of secreted factors without direct cell-to-cell contact.
The study utilized quantitative proteomics (DIA and TMT mass spectrometry) to profile the astrocyte secretome. Biotinylated peptide pull-down assays identified protein interactions, while Seahorse extracellular flux analysis and MitoTracker imaging assessed mitochondrial health. Finally, in vivo efficacy was tested in RTT mouse models through behavioral assessments such as open-field and rotarod tests.
Molecular Mechanisms of IGF1(1-3) Action
The researchers identified Insulin-like growth factor binding protein 2 (IGFBP2) as a major inhibitory factor secreted by RTT astrocytes. IGFBP2 acts as a "molecular sponge," sequestering free IGF1 and preventing it from activating neuronal receptors necessary for synaptogenesis.
Crucially, the IGF1(1-3) peptide does not merely mimic IGF1; it binds to IGFBP2 and triggers its degradation via the proteasomal pathway. This "hitman" mechanism restores IGF1 bioavailability. Furthermore, the accumulation of IGFBP2 was linked to mitochondrial fragmentation and metabolic failure in astrocytes, both of which were reversed by peptide treatment.
Key Results
The study demonstrated that KO astrocytes significantly reduce excitatory synapse formation in healthy neurons. Treatment of these KO astrocytes with the IGF1(1-3) peptide restored synaptic markers to WT levels. Specifically, the colocalization of synaptic markers PSD-95 and Bassoon increased from approximately 33% in untreated KO conditions to 55% following treatment.
Proteomic analysis revealed that the peptide partially reversed the expression of 75% (2406 out of 3216) of differentially expressed proteins in KO astrocytes. Metabolically, peptide treatment doubled extracellular ATP release in KO astrocytes, matching WT levels. In vivo, daily injections of the peptide significantly improved locomotor deficits in both global and astrocyte-specific MECP2 knockout mice.
Discussion and Future Directions
These findings establish astrocytes as a primary therapeutic target in Rett Syndrome. By clearing the inhibitory IGFBP2 protein, IGF1-derived peptides restore both astrocyte metabolism and neuronal connectivity. While the study provides strong evidence for mitochondrial rescue, further biochemical validation of specific oxidative phosphorylation proteins is warranted. Future research should explore astrocyte-specific delivery of IGF1 mimetics and investigate whether direct modulation of IGFBP2 levels could serve as a broader therapeutic strategy for other neurodevelopmental disorders involving glial dysfunction and metabolic deficits.
Summary updated